PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy (PEACH)

PEACH TRIAL- Precision mEdicine and Adoptive Cellular tHerapy for the Treatment of Recurrent Neuroblastoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendritic Cells (DCs) (TTRNA-DCs), Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) and Autologous G-CSF mobilized Hematopoietic Stem Cells (HSCs)).

Study Overview

• Status: Recruiting
• Conditions: Neuroblastoma; Diffuse Intrinsic Pontine Glioma
• Intervention / Treatment: Biological: Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)

• Study Type: Interventional
• Enrollment (Estimated): 24
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: G Bergendahl, MSN; Phone Number: (704) 355-1220; Email: genevieve.bergendahl@atriumhealth.org

Study Locations

• United States
  • Florida
    • Gainesville, Florida, United States, 32611
      • Recruiting
      • University of Florida
      • Contact: Marcia Hodik, RN; Phone Number: 352-273-9050; Email: marcia.hodik@neurosurgery.ufl.edu
      • Principal Investigator: John Ligon, MD
  • North Carolina
    • Charlotte, North Carolina, United States, 28204
      • Active, not recruiting
      • Levine Children's Hospital
  • Pennsylvania
    • Hershey, Pennsylvania, United States, 17033
      • Recruiting
      • Penn State Milton S. Hershey Medical Center and Children's Hospital
      • Contact: Suzanne Treadway; Email: streadway@hmc.psu.edu
      • Principal Investigator: Valerie Brown, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 30 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subjects must have proven pediatric cancer with confirmation at diagnosis or at the time of recurrence/progression and clinical determination of disease for which there is no known effective curative therapy or disease that is refractory to established proven therapies fitting into one of the following categories:
• Disease Status:

High Risk Neuroblastoma-

1. Patients that have relapsed following standard of care therapy or having progressed during standard of care therapy and non-responsive/progressive to accepted curative chemotherapy.
2. Neuroblastoma must be age >12 months at enrollment

Diffuse Intrinsic Pontine (or other brain stem) Glioma

1. Newly-diagnosed patients willing to undergo biopsy
2. Must be within 2 months of diagnosis and prior to starting radiation

3. DIPG must be ≥ 3 years of age at enrollment

   • All subjects must be age ≤ 30 years at enrollment
   • Patient and/or parents/guardian willing to consent to biopsy for obtaining tumor material for confirmatory diagnosis and/or tumor RNA extraction and amplification.
   • Subjects must have measurable disease as defined Per section 8 at the time of biopsy and tumor must be accessible for biopsy. Tumor samples submitted for analysis must contain >30% viable tumor tissue to qualify. In addition, subjects with NB disease confined to the bone marrow are eligible to enroll if the degree of marrow involvement is expected to be >30%.
   • Current disease state must be one for which there is currently no known effective therapy
   • Specimens will be obtained only in a non-significant risk manner and not solely for the purpose of investigational testing.
   • Lansky or Karnofsky Score must be ≥ 60

   • Bone Marrow:

     1. ANC (Absolute neutrophil count) ≥ 1000/µl (unsupported)
     2. Platelets ≥ 100,000/µl (can be transfused)
     3. Hemoglobin > 8 g/dL (can be transfused)
   • Renal: Serum creatinine ≤ upper limit of institutional normal.

   • Adequate liver function must be demonstrated, defined as:

     1. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age AND
     2. ALT (SGPT) ≤ 3 times upper limit of normal (ULN) for age
     3. AST (SGOT) ≤ 3 times upper limit of normal (ULN) for age.
   • Subjects with CNS disease currently taking steroids must have been on a stable dose of steroids for at least one week prior to their biopsy and must not have progressive hydrocephalus at enrollment.
   • A negative serum pregnancy test is required for female participants of childbearing potential (≥13 years of age or after onset of menses)
   • Both male and female post-pubertal study subjects need to agree to use one of the more effective birth control methods during treatment and for six months after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrel implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended.
   • Informed Consent: All subjects and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines
   • Post-Biopsy: Patients with post-biopsy neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration.

Exclusion Criteria:

• Absence of tumor on biopsy specimen or a diagnosis other than NBL or glioma on biopsy
• Known autoimmune or immunosuppressive disease or human immunodeficiency virus infection.
• Subjects with significant renal, cardiac, pulmonary, hepatic or other organ dysfunction.
• Prior allergic reaction to GM-CSF or Td.
• Subjects who have received any cytotoxic chemotherapy within the last 7 days prior to biopsy or focal radiotherapy in the case of patients with diffuse intrinsic pontine (or other brain stem) gliomas
• Subjects with NBL who have received any radiotherapy to the primary sample site within the last 14 days (radiation may be included in treatment decision after biopsy).
• Subjects receiving any investigational drug concurrently.
• Subjects with uncontrolled serious infections or a life-threatening illness (unrelated to tumor)
• Subjects with any other medical condition, including malabsorption syndromes, mental illness or substance abuse, deemed by the Investigator to be likely to interfere with the interpretation of the results or which would interfere with a subject's ability to sign or the legal guardian's ability to sign the informed consent, and subject's ability to cooperate and participate in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1: Subjects with Diffuse Intrinsic Pontine Glioma (DIPG).; This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT: Dose Level 1: 3 x10^7 cells/kg Dose Level +1: 3 x10^8 cells/kg Dose Level -1: 3 x10^6 cells/kg The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects).	Biological: Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT); There will be two immunotherapy products manufactured and administered to subjects enrolled on this trial. The first product will be autologous dendritic cells (DCs) loaded with total tumor messenger ribonucleic acid (mRNA) (TTRNA) derived from malignant tumors. The second product will be autologous T lymphocytes stimulated ex vivo against TTRNA antigens for autologous transfer (TTRNA-xALT). DCs are professional antigen-presenting cells critical for the initiation of B and T-cell responses in vivo.; Other Names: xALT
Experimental: Arm 2: Relapsed/Refractory Neuroblastoma (NB); This Phase I study is will utilize a standard 3+3 dose escalation design to establish the MTD and will evaluate the following three pre-specified dose levels of xALT: Dose Level 1: 3 x10^7 cells/kg Dose Level +1: 3 x10^8 cells/kg Dose Level -1: 3 x10^6 cells/kg The dose escalation scheme will be evaluated for Arm 1 and Arm 2 separately. For each Study Arm, a minimum of 4 DLT evaluable subjects and a maximum of 12 DLT evaluable subjects will be enrolled (a total of 8 to 24 DLT evaluable subjects).	Biological: Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT); There will be two immunotherapy products manufactured and administered to subjects enrolled on this trial. The first product will be autologous dendritic cells (DCs) loaded with total tumor messenger ribonucleic acid (mRNA) (TTRNA) derived from malignant tumors. The second product will be autologous T lymphocytes stimulated ex vivo against TTRNA antigens for autologous transfer (TTRNA-xALT). DCs are professional antigen-presenting cells critical for the initiation of B and T-cell responses in vivo.; Other Names: xALT

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants with Dose Limiting Toxicities as a Measure of Safety and Tolerability	To evaluate the dose-limiting toxicities (DLTs) and to establish the maximum tolerated dose (MTD) of treating children with molecular targeted therapy in combination with adoptive cellular therapy	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	To evaluate the overall safety profile of study treatment	2 years plus 30 days
Number of Participants that are able to have vaccine produced and delivered	To evaluable the feasibility of producing and administering the protocol directed therapy	2 years
Number of participants with progression free survival (PFS) during study	To determine the activity of treatments chosen based on Progression free survival (PFS)	7 years
Number of participants with overall survival (OS) during study	To determine the activity of treatments chosen based on Overall Survival (OS)	7 years
Determine the Overall Response Rate (ORR) of Participants using INSS Response Evaluation Criteria for NB and RANO criteria for DIPG	To determine the activity of treatments chosen based on Overall Response Rate (ORR)	2 years

Collaborators and Investigators

• Sponsor: University of Florida
• Collaborators: Beat Childhood Cancer Research Consortium
• Investigators: Study Chair: Duane Mitchell, M.D., Ph.D., University of Florida; Study Chair: Giselle Sholler, MD, Beat Childhood Cancer at Atrium Health

Publications and helpful links

Helpful Links

• Beat Childhood Cancer Consortium website

Study record dates

Study Major Dates

• Study Start (Actual): September 20, 2021
• Primary Completion (Estimated): September 1, 2025
• Study Completion (Estimated): September 1, 2030

Study Registration Dates

• First Submitted: April 6, 2021
• First Submitted That Met QC Criteria: April 7, 2021
• First Posted (Actual): April 8, 2021

Study Record Updates

• Last Update Posted (Actual): April 11, 2024
• Last Update Submitted That Met QC Criteria: April 9, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Brain Neoplasms; Central Nervous System Neoplasms; Nervous System Neoplasms; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Brain Stem Neoplasms; Infratentorial Neoplasms; Glioma; Neuroblastoma; Diffuse Intrinsic Pontine Glioma
• Other Study ID Numbers: BCC017

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No